Key Takeaways
- • FDA submitted a $7.2 billion budget proposal to Congress for fiscal year 2027, representing a $232 million (3.3%) increase over the FY 2026 enacted level, comprised of $3.3 billion in appropriations and $3.9 billion in user fees.
- • The agency rejected a petition seeking partial 510(k) exemption for radiology software products, including Computer-Aided Detection/Diagnosis (CAD), Computer-Aided Triage and Notification (CADt), and medical image analyzers, determining that exemptions would not serve the public interest and lack legal authorization.
- • Former FDA Center for Devices and Radiological Health (CDRH) leadership launched White Oak 66 Capital, a new venture capital fund co-founded by ex-CDRH Director Jeff Shuren, Chief Scientist and Deputy Director Douglas Kelly, and Ross Segan (former Office of Product Evaluation and Quality director).
Summary
The FDA advanced three significant developments this week affecting the medtech regulatory landscape and venture capital dynamics. The agency formally submitted its fiscal year 2027 budget proposal to Congress, requesting $7.2 billion in total funding—a modest 3.3% increase from the prior year's enacted level of $6.8 billion. The budget consists of $3.3 billion in appropriations and $3.9 billion in user fees, demonstrating continued reliance on industry funding mechanisms to support regulatory operations.
In a closely watched regulatory decision, the FDA issued a final response letter rejecting a petition for partial exemption from 510(k) premarket notification requirements for certain radiological software products. The petition sought to exempt Computer-Aided Detection and Diagnosis (CAD), Computer-Aided Triage and Notification (CADt), medical image analyzers, and related radiological diagnostic software from 510(k) submission. The agency determined that granting such exemptions would not be in the public interest and lacked legal authority to proceed, signaling the FDA's cautious stance toward deregulation of medical device software despite growing industry pressure.
The week also witnessed a significant leadership realignment in the medtech venture capital space. Former CDRH officials have launched White Oak 66 Capital, a venture fund co-founded by Jeff Shuren (former CDRH Director), Douglas Kelly (former Chief Scientist and Deputy Director), and Ross Segan (former director of the Office of Product Evaluation and Quality). This departure of top regulatory officials into venture capital underscores the substantial career opportunities emerging at the intersection of FDA expertise and private capital deployment, potentially affecting regulatory continuity and institutional knowledge at the agency.
These three developments collectively signal mixed regulatory dynamics: modest budgetary growth that may constrain the FDA's capacity, resistance to software deregulation that maintains current compliance requirements for medtech companies, and selective departure of senior CDRH leadership to capitalize on private sector investment opportunities.
In a closely watched regulatory decision, the FDA issued a final response letter rejecting a petition for partial exemption from 510(k) premarket notification requirements for certain radiological software products. The petition sought to exempt Computer-Aided Detection and Diagnosis (CAD), Computer-Aided Triage and Notification (CADt), medical image analyzers, and related radiological diagnostic software from 510(k) submission. The agency determined that granting such exemptions would not be in the public interest and lacked legal authority to proceed, signaling the FDA's cautious stance toward deregulation of medical device software despite growing industry pressure.
The week also witnessed a significant leadership realignment in the medtech venture capital space. Former CDRH officials have launched White Oak 66 Capital, a venture fund co-founded by Jeff Shuren (former CDRH Director), Douglas Kelly (former Chief Scientist and Deputy Director), and Ross Segan (former director of the Office of Product Evaluation and Quality). This departure of top regulatory officials into venture capital underscores the substantial career opportunities emerging at the intersection of FDA expertise and private capital deployment, potentially affecting regulatory continuity and institutional knowledge at the agency.
These three developments collectively signal mixed regulatory dynamics: modest budgetary growth that may constrain the FDA's capacity, resistance to software deregulation that maintains current compliance requirements for medtech companies, and selective departure of senior CDRH leadership to capitalize on private sector investment opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.